8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

Boerekamps, A., Vanwolleghem, T., van der Valk, M., van den Berk, G. E., van Kasteren, M., Posthouwer, D., … Rijnders, B. J. (2019, March 1). 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study). Journal of Hepatology. Elsevier B.V. https://doi.org/10.1016/j.jhep.2018.10.032